Patentability of Chipscreen's chidamide-associated drug challenged by Chinese rival
An anticancer-drug patent held by Shenzhen Chipscreen Biosciences has been challenged by its Chinese peer Nanjing Chia-Tai Tianqing Pharmaceutical, the Shanghai-listed patentee disclosed in a recent stock exchange filing. The disputed...To view the full article, register now.
Already a subscriber? Click here to view full article